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Over the past decade, numerous publications have 
stressed the importance of IFN-I in the pathogenesis of 
systemic lupus erythematosus (SLE), but their assays 
typically used microarrays and/or quantitative PCR 
(qPCR) and thus appear to be laborious and not well 
suited for use in clinical practice. In the previous issue of 
Arthritis Research Th  erapy, Li and colleagues [1] have 
investigated a much simpler methodology to measure the 
level of activation of IFN-I in patients with SLE. Th  ey 
measured the expression of CD64 (FcγRI) by ﬂ  ow 
cytometry on monocytes and demonstrated high levels 
in SLE compared with healthy controls. Th   e authors also 
showed that CD64 levels correlated with IFN-stimulated 
gene (ISG) expression (by qPCR) and disease activity (by 
Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI)) and that CD64 was downregulated in four 
patients who received pulse methylprednisolone therapy. 
As expected, CD64 was induced in normal monocytes by 
IFN-I in vitro. Similar ﬁ  ndings have been obtained in SLE 
monocytes by ﬂ  ow cytometry in another study focused 
on sialoadhesin (Siglec-1 or CD169), although this assay 
required indirect immuno  ﬂ  uores  cence staining [2]. Both 
these molecules appear promising as biomarkers of IFN-I 
activation in SLE.
Th   e clinical signiﬁ  cance of IFN-I pathway activation in 
SLE is multifaceted. First, the pathway has been 
implicated in the pathogenesis of the disease, and 
therefore targeted therapies against IFN-I are currently in 
clinical trials. Second, IFN-I activation may identify a 
subset of SLE patients with potential diagnostic, prog-
nostic and therapeutic implications. Th  ird, change in 
IFN-I activity levels may reﬂ  ect change in disease activity 
and thus help clinical management of the disease. In this 
context, the data by Li and colleagues on CD64 
expression have clinical relevance as they might facilitate 
research in all of the above areas with a simple tool.
Th  e implication of IFN-I in SLE pathogenesis comes 
from multiple pieces of evidence, including genetic, gene 
expression association studies, and induction of SLE by 
therapeutic administration of IFN-I [3]. Th  e potential 
mechanisms by which IFN-I may promote inﬂ  ammation 
and autoimmunity have been reviewed recently and 
include activation of immature dendritic cells and break 
of peripheral tolerance, augmentation of humoral 
immunity pathways with production of pathogenic 
antibodies, induction of Th   1 cells, chemokine production, 
and priming of myeloid cells for enhanced responses to 
inﬂ  ammatory stimuli [4]. Th  e emerging evidence about 
the pathogenic role of IFN-I in SLE led to the recent 
introduction in clinical trials of several anti-IFN anti-
bodies. Th  is exciting new era of IFN-I targeting should 
greatly beneﬁ  t from simple biomarkers of the pathway’s 
activity, such as CD64 and CD169 expression. Th  is  would 
facilitate stratiﬁ  cation of SLE patients according to IFN-I 
activation, as well as monitoring of the degree of IFN-I 
inhibition during therapy - adequate to suppress disease 
activity, but not excessive to cripple immunosurveillance.
Cross-sectional studies, including our own and the 
study by Li and colleagues, have shown that IFN-I 
activation in SLE is present in about half of adult patients 
and it is associated with disease activity, renal involve-
ment, as well as autoantibodies to dsDNA, and RNA 
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group of patients might represent a diﬀ  erent subclass of 
the disease where the IFN-I pathway is dominant and 
therefore its therapeutic targeting most beneﬁ  cial. Th  e 
design of those studies, however, leaves open the 
possibility that some patients may be positive for IFN 
only intermittently, especially during disease ﬂ  ares, and 
again negative after aggressive therapy, such as with pulse 
methylprednisolone [1,5]. More research needs to be 
done in this area before conclusions can be drawn. We 
believe that although SLE patients should be stratiﬁ  ed in 
clinical trials of anti-IFN therapy, patients negative for 
IFN-I activation should not be excluded from the trials.
Two longitudinal studies failed to show ability of IFN-I 
activation to parallel acute changes of disease activity 
[6,7]. However, one of those studies used microarray data 
(which is less accurate than qPCR) for their ISG score [7] 
and both had only few patients with more than two visits. 
Moreover, IFN-regulated chemokine levels did parallel 
disease activity in a larger study [8]. Interestingly, high 
baseline levels of these chemokines substantially increased 
the risk for lupus ﬂ  are, especially a renal one, in the next 
year [8]. Flares were also increased for patients with high 
baseline ISG scores, but in a more delayed manner [6]. In 
our experience, about 30 to 40% of patients, followed 
longi  tudinally for at least 2 years, demonstrate parallel 
courses of SLEDAI and ISG scores [9]. Based on the 
above studies, it appears that the matter has not been 
resolved yet, but it is possible that ISG scores work as 
biomarkers of disease activity only in a subgroup of patients, 
and not necessarily the ones with high baseline IFN-I 
activity. Other pathway signatures or a combination of those 
might be eventually required to evaluate all patients [10].
Although measurement of monocyte CD64 and CD169 
expression appears promising, it is likely not speciﬁ  c for 
either IFN-I or SLE disease activity. Similar to other ISGs, 
both can be induced by viral infection and IFN-γ, whereas 
CD64 expression may also be induced by IL-10 [1,11,12]. 
Th   us, at this point, none of the above gene measurements 
can be expected to substitute for clinical judgment to 
diﬀ   erentiate lupus ﬂ   are from infection. Furthermore, 
before these new monocyte cell surface markers can fulﬁ  ll 
their promise for ease and eﬃ   ciency of IFN-I detection, 
they will need to be validated against currently used IFN-I 
molecular assays (especially qPCR) in carefully conducted 
large longitudinal prospective studies of SLE patients.
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